CIP
ALXN

Convergence Investment Partners’s Alexion Pharmaceuticals ALXN Stock Holding History

Convergence Investment Partners’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,728
Closed -$270K – 285
2020
Q4 		$270K Sell
1,728
-7,869
-82% -$1.01M 0.14% 146
2020
Q3 		$1.1M Buy
9,597
+547
+6% +$59K 0.38% 95
2020
Q2 		$1.02M Buy
+9,050
New +$961K 0.35% 98
2019
Q4 		– Sell
-11,997
Closed -$1.18M – 337
2019
Q3 		$1.18M Buy
+11,997
New +$1.35M 0.33% 112
2018
Q2 		– Sell
-575
Closed -$64K – 993
2018
Q1 		$64K Buy
+575
New +$68.7K 0.01% 407
2014
Q4 		– Sell
-5,135
Closed -$851K – 439
2014
Q3 		$851K Sell
5,135
-3,238
-39% -$532K 0.12% 262
2014
Q2 		$1.31M Buy
+8,373
New +$1.32M 0.17% 189

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $15.3B AUM 50.95% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $7.94B AUM 55.6% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $14.1B AUM 58.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $4.65B AUM 56.47% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return